Achieve Life Sciences, Inc. (ACHV) — SEC Filings
Achieve Life Sciences, Inc. (ACHV) — 32 SEC filings. Latest: 10-K (Mar 24, 2026). Includes 14 8-K, 6 10-Q, 5 SC 13G.
View Achieve Life Sciences, Inc. on SEC EDGAR
Overview
Achieve Life Sciences, Inc. (ACHV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 24, 2026: Achieve Life Sciences, Inc. (ACHV) is a late-stage clinical specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence. The company reported no revenue for the fiscal year ended December 31, 2025, as it remains in the development phase. A significant development in
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bearish, 28 neutral, 2 mixed. The dominant filing sentiment for Achieve Life Sciences, Inc. is neutral.
Filing Type Overview
Achieve Life Sciences, Inc. (ACHV) has filed 3 10-K, 14 8-K, 6 10-Q, 2 DEF 14A, 2 SC 13G/A, 5 SC 13G with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ACHV's 24 recent filings, 3 were flagged as high-risk, 15 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$48,800,000 |
| EPS | -$1.00 |
| Debt-to-Equity | 0.0 |
| Cash Position | $18,600,000 |
| Operating Margin | N/A |
| Total Assets | $33,500,000 |
| Total Debt | $0 |
Key Executives
- Richard Stewart
- John Bencich
- Dr. Cherise Smith
- Ms. Jennifer Cook
Industry Context
The smoking and nicotine cessation market is a significant public health area with substantial unmet needs, evidenced by millions of users in the US alone. While established therapies exist, there is a continuous demand for more effective and convenient options. Achieve Life Sciences aims to differentiate cytisinicline through its efficacy, safety profile, and dosing flexibility, positioning it as a potentially valuable new entrant.
Top Tags
corporate-governance (5) · 10-Q (4) · financials (4) · Biotechnology (3) · material-agreement (3) · life-sciences (3) · Pharmaceuticals (2) · Nicotine Dependence (2) · Clinical Trials (2) · 8-K (2)
Executive Compensation
From the most recent 10-K filing (Mar 24, 2026):
- John B. (Jay) Howlett — Chief Executive Officer: $470,000
- Richard (Rick) Charles — Chief Financial Officer: $325,000
- Dr. William (Bill) Heikkinen — Chief Medical Officer: $325,000
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $103,958,994 | As of June 30, 2025, indicating market capitalization |
| Shares of common stock outstanding | 53,239,988 | As of March 24, 2026 |
| PDUFA targeted action date | June 20, 2026 | For cytisinicline NDA for smoking cessation |
| Anticipated commercial launch year | 2027 | First-half 2027 for cytisinicline |
| Adults in the United States who smoke | 29 million | Represents a significant target market for cytisinicline |
| Adults in the United States who utilize e-cigarettes | 17 million | Represents another significant target market for cytisinicline |
| Worldwide deaths annually | 8 million | Attributable to tobacco use, highlighting the public health crisis cytisinicline aims to address |
| Net Loss | $39.986M | Increased from $27.467M in 2024 for the nine months ended September 30, 2025 |
| Total Operating Expenses | $40.149M | Increased from $26.879M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $19.124M | Increased from $15.521M in 2024 for the nine months ended September 30, 2025 |
| General and Administrative Expenses | $21.025M | Increased from $11.358M in 2024 for the nine months ended September 30, 2025 |
| Cash, Cash Equivalents and Marketable Securities | $48.114M | As of September 30, 2025, up from $34.360M at December 31, 2024 |
| Net Cash Provided by Financing Activities | $45.264M | For the nine months ended September 30, 2025, primarily from public offerings |
| Accumulated Deficit | $245.564M | As of September 30, 2025, indicating historical losses |
| Net Cash Used in Operating Activities | $31.488M | For the nine months ended September 30, 2025, reflecting cash burn |
Frequently Asked Questions
What are the latest SEC filings for Achieve Life Sciences, Inc. (ACHV)?
Achieve Life Sciences, Inc. has 32 recent SEC filings from Feb 2024 to Mar 2026, including 14 8-K, 6 10-Q, 5 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ACHV filings?
Across 32 filings, the sentiment breakdown is: 2 bearish, 28 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Achieve Life Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Achieve Life Sciences, Inc. (ACHV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Achieve Life Sciences, Inc.?
Key financial highlights from Achieve Life Sciences, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ACHV?
The investment thesis for ACHV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Achieve Life Sciences, Inc.?
Key executives identified across Achieve Life Sciences, Inc.'s filings include Richard Stewart, John Bencich, Dr. Cherise Smith, Ms. Jennifer Cook.
What are the main risk factors for Achieve Life Sciences, Inc. stock?
Of ACHV's 24 assessed filings, 3 were flagged high-risk, 15 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Achieve Life Sciences, Inc.?
Forward guidance and predictions for Achieve Life Sciences, Inc. are extracted from SEC filings as they are enriched.